Frederic Guerard, head of Novartis’ ophthalmology franchise, explains why the global giant was the last strategic standing in the competitive bidding to acquire the promising, but very early stage, start-up. Novartis will resume testing of the new presbyopia-correcting ophthalmic solution, now dubbed UNR-844.
Frederic Guerard is the Worldwide Business Franchise Head, Ophthalmology for Novartis after having served as Global Business Franchise Head Pharmaceuticals for Alcon.
Meet Our New Host
Joining the company in 2019, to create and manage a new line of podcasts, publications, and other editorial products.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.